Literature DB >> 23712199

Prostate cancer: intermittent ADT--tales from a 27-year odyssey.

Laurence Klotz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23712199     DOI： 10.1038/nrurol.2013.118

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.

Authors:  Steven L Chang; Joseph C Liao; Rajesh Shinghal
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

3.  Intermittent endocrine therapy for advanced prostate cancer.

Authors:  L H Klotz; H W Herr; M J Morse; W F Whitmore
Journal:  Cancer       Date:  1986-12-01       Impact factor: 6.860

4.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.

Authors:  N Bruchovsky; P S Rennie; A J Coldman; S L Goldenberg; M To; D Lawson
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

5.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

Review 6.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

7.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

Review 8.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Authors:  Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

9.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Stuart J Pocock; Stephen J W Evans; Douglas G Altman
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.